{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T21:57:39Z","timestamp":1725487059735},"reference-count":20,"publisher":"FapUNIFESP (SciELO)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Col. Bras. Cir."],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:p>OBJETIVO: Avaliar em pacientes com c\u00e2ncer de mama a express\u00e3o imunoistoqu\u00edmica da cox-2 antes da quimioterapia prim\u00e1ria com 5-fluorouracil, epirrubicina e ciclofosfamida (FEC) e a associa\u00e7\u00e3o desta com tamanho inicial do tumor, estado linfonodal, receptores hormonais, express\u00e3o da Her-2 e com a resposta cl\u00ednica e anatomopatol\u00f3gica. M\u00c9TODOS: Estudo retrospectivo com 41 mulheres portadoras do diagn\u00f3stico histopatol\u00f3gico de carcinoma ductal de mama. Foram submetidas \u00e0 quimioterapia prim\u00e1ria com esquema FEC (5-fluorouracil, epirrubicina e ciclofosfamida) na dosagem de 500mg\/m2, 75mg\/m2 e 500 mg\/m2, respectivamente. Os crit\u00e9rios de inclus\u00e3o foram intervalo et\u00e1rio entre 30 e 70 anos, estadiamento II a IIIA, ap\u00f3s comprova\u00e7\u00e3o da aus\u00eancia de met\u00e1stase, tumor prim\u00e1rio de mama, \u00fanico e unilateral, tipo histol\u00f3gico ductal invasivo e aus\u00eancia de cardiopatia e gesta\u00e7\u00e3o. Para avalia\u00e7\u00e3o da express\u00e3o da prote\u00edna Her 2 neuutilizaram-se anticorpos monoclonais de coelho. Para visibilizar a express\u00e3o da prote\u00edna cox-2 utilizaram-se anticorpos policlonais obtidos do soro de cabras. A avalia\u00e7\u00e3o da resposta cl\u00ednica ao tratamento foi realizada por exame f\u00edsico mensurando-se o maior eixo tumoral por paqu\u00edmetro. As medidas foram realizadas \u00e0 admiss\u00e3o e ap\u00f3s os ciclos de quimioterapia prim\u00e1ria. Ap\u00f3s tr\u00eas sess\u00f5es quimioter\u00e1picas com intervalos de 21 dias realizou-se o procedimento cir\u00fargico. Adotaram-se os crit\u00e9rios do RECIST. Ap\u00f3s a opera\u00e7\u00e3o foi avaliada a resposta anatomopatol\u00f3gica local, sendo considerada completa quando da aus\u00eancia de neoplasia invasiva e do componente in situ. Na avalia\u00e7\u00e3o imumoistoqu\u00edmica para os receptores de estrog\u00eanio utilizaram-se estrogen receptor NCL-ER6F11 e para progesterona, progesterone receptor, NCL-PGR-312 considerando positiva quando da colora\u00e7\u00e3o em 10% ou mais das c\u00e9lulas tumorais. RESULTADOS: A distribui\u00e7\u00e3o segundo estadiamento cl\u00ednico UICC verificaram-se seis no est\u00e1dio IIA (14,6%), 22 no est\u00e1dio IIB (53,6%) e 13 est\u00e1dio IIIA (31,8%). A avalia\u00e7\u00e3o cl\u00ednica inicial do maior eixo tumoral variou de 2,5 a 15 cm e mediana de 5 cm. Foram identificadas 14 pacientes (34,1%) com estado linfonodal negativo e 27 positivo (65,9%). Observou-se que 19 (46,3%) apresentavam-se no menacme e 22 (53,6%) na menopausa. CONCLUS\u00c3O: Houve associa\u00e7\u00e3o da express\u00e3o da cox-2 \u00e0 fatores de pior progn\u00f3stico no c\u00e2ncer de mama como estado linfonodal positivo, receptores hormonais negativos e express\u00e3o da Her-2.<\/jats:p>","DOI":"10.1590\/s0100-69912010000500003","type":"journal-article","created":{"date-parts":[[2010,12,20]],"date-time":"2010-12-20T06:36:40Z","timestamp":1292827000000},"page":"323-327","source":"Crossref","is-referenced-by-count":5,"title":["Cox-2 e sua associa\u00e7\u00e3o com fatores progn\u00f3sticos e resposta \u00e0 quimioterapia prim\u00e1ria em pacientes com c\u00e2ncer de mama"],"prefix":"10.1590","volume":"37","author":[{"given":"Renato de Lima","family":"Rozenowicz","sequence":"first","affiliation":[{"name":"Irmandade da Santa Casa de S\u00e3o Paulo,  BR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto Euz\u00e9bio dos","family":"Santos","sequence":"additional","affiliation":[{"name":"Irmandade da Santa Casa de S\u00e3o Paulo,  BR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Antonieta Longo Galv\u00e3o","family":"Silva","sequence":"additional","affiliation":[{"name":"FCMSCSP"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio Francisco Oliveira","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Irmandade da Santa Casa de S\u00e3o Paulo,  BR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9 Lima de","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Irmandade da Santa Casa de S\u00e3o Paulo,  BR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliane Baratela","family":"Ulson","sequence":"additional","affiliation":[{"name":"FCMSCSP,  BR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vilmar Marques","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Irmandade da Santa Casa de S\u00e3o Paulo,  BR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Aoki","sequence":"additional","affiliation":[{"name":"Irmandade da Santa Casa de S\u00e3o Paulo,  -BR"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"key":"ref1","series-title":"Estimativa 2008: Incid\u00eancia de c\u00e2ncer no Brasil","year":"2007"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.critrevonc.2006.01.003","article-title":"Cyclooxygenase-2 as a target for anticancer drug development. [Review]","volume":"59","author":"M\u00e9ric JB","year":"2006","journal-title":"Crit Rev Oncol Hematol."},{"key":"ref3","doi-asserted-by":"crossref","first-page":"18563","DOI":"10.1074\/jbc.M010787200","article-title":"Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice","volume":"276","author":"Liu CH","year":"2001","journal-title":"J Biol Chem."},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1593\/neo.08568","article-title":"The malignant phenotype of breast cancer cells is reduced by cox-2 silencing","volume":"10","author":"Stasinopoulos I","year":"2008","journal-title":"Neoplasia."},{"key":"ref5","series-title":"Manual de padroniza\u00e7\u00e3o de laudos histopatol\u00f3gicos","first-page":"p 265","volume-title":"Les\u00f5es benignas n\u00e3o neopl\u00e1sicas e neoplasias da mama","author":"Abreu e Lima M C","year":"2005","edition":"3"},{"key":"ref6","first-page":"632","article-title":"Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer","volume":"62","author":"Ristim\u00e4ki A","year":"2002","journal-title":"Cancer Res","ISSN":"http:\/\/id.crossref.org\/issn\/0008-5472","issn-type":"print"},{"issue":"8","key":"ref7","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ejca.2006.01.026","article-title":"RECIST revisited: a review of validation studies on tumor assessment","volume":"42","author":"Therasse P","year":"2006","journal-title":"Eur J Cancer."},{"key":"ref8","first-page":"297","article-title":"Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome","volume":"180","author":"Sataloff DM","year":"1995","journal-title":"J Am Coll Surg."},{"key":"ref9","first-page":"1676","article-title":"Cyclooxygenase-2 expression in human breast cancer and adjacent ductal carcinoma in situ","volume":"62","author":"Half E","year":"2002","journal-title":"Cancer Res.","ISSN":"http:\/\/id.crossref.org\/issn\/0008-5472","issn-type":"print"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1002\/cncr.11437","article-title":"Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma","volume":"97","author":"Denkert C","year":"2003","journal-title":"Cancer."},{"key":"ref11","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1136\/jcp.55.6.429","article-title":"Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer","volume":"55","author":"Costa C","year":"2002","journal-title":"J Clin Pathol."},{"key":"ref12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1590\/S0104-42302006000400031","article-title":"Express\u00e3o da COX-2 e CD115 no c\u00e2ncer de mama e sobrevida livre de doen\u00e7a","volume":"52","author":"Grudzinski M","year":"2006","journal-title":"Rev Assoc Med Bras."},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/sj.bjc.6603067","article-title":"COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer","volume":"94","author":"Timoshenko AV","year":"2006","journal-title":"Br J Cancer."},{"key":"ref14","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ejso.2006.02.024","article-title":"Cyclooxygenase-2 (COX-2) mRNA expression and hormone receptor status in breast cancer","volume":"32","author":"McCarthy K","year":"2006","journal-title":"Eur J Surg Oncol."},{"key":"ref15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jsbmb.2006.09.029","article-title":"Role of the progesterone receptor (PR) in the regulation of inflammatory response pathways and aromatase in the breast","volume":"102","author":"Mendelson C","year":"2006","journal-title":"J Steroid Biochem Mol Biol."},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/sj.onc.1207295","article-title":"Regulation of HER-2 oncogene expression by cyclooxygenase-2 and prostaglandin E2","volume":"23","author":"Benoit V","year":"2004","journal-title":"Oncogene","ISSN":"http:\/\/id.crossref.org\/issn\/0950-9232","issn-type":"print"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/sj.bjc.6601534","article-title":"COX-2 expression is associated with aggressive phenotype in ductal carcinoma in situ","volume":"90","author":"Boland GP","year":"2004","journal-title":"Br J Cancer."},{"key":"ref18","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1186\/bcr1313","article-title":"Relationship between the expression of cyclooxygenase 2 and MDR1\/P-glycoprotein in invasive breast cancer and their prognostic significance","volume":"7","author":"Surowiak P","year":"2007","journal-title":"Breast Cancer Res."},{"key":"ref19","first-page":"2283","article-title":"Cyclooxigenase-2 expression after preoperative chemoradiation correlates with more frequent esophageal cancer recurrence","volume":"28","author":"Yoshikawa R","year":"2009","journal-title":"World J Gastroenterol,"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/1471-2407-6-182","article-title":"Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum\/paclitaxel containing chemotherapy in advanced ovarian cancer","volume":"6","author":"Ferrandina G","year":"2006","journal-title":"BMC Cancer."}],"container-title":["Revista do Col\u00e9gio Brasileiro de Cirurgi\u00f5es"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/rcbc\/v37n5\/03.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T18:18:25Z","timestamp":1495822705000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0100-69912010000500003&lng=pt&tlng=pt"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0100-69912010000500003"],"URL":"https:\/\/doi.org\/10.1590\/s0100-69912010000500003","relation":{},"ISSN":["0100-6991"],"issn-type":[{"value":"0100-6991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}